AllSci News
Ipsen's Phase III Bylvay failure extends long search for biliary atresia therapy
Ipsen (Euronext: IPN; ADR: IPSEY) reported on July 24 that the Phase III BOLD trial of odevixibat (Bylvay) in biliary atresia failed to meet its primary...
NIH backs Mount Sinai's FSH-blocking antibody for Down syndrome Alzheimer's
Icahn School of Medicine at Mount Sinai has received a USD 1,210,250 NIH R01 grant to test whether blocking follicle-stimulating hormone (FSH) can reduce...
Phoenix Nest gets NIH backing for Sanfilippo syndrome gene therapy manufacturing
Phoenix Nest, a Brooklyn, New York-based biotechnology company, has received a USD 1.49 million NIH SBIR grant to fund manufacturing and analytical...
Thyora Therapeutics launches with Moffitt covalent chemistry platform
Thyora Therapeutics, a Tampa, Florida-based biotechnology company, emerged from stealth with an exclusive worldwide license to covalent chemistry technology...
Genmab and AbbVie's epcoritamab fails survival endpoint in confirmatory DLBCL trial
Genmab and AbbVie clarified on July 23 that overall survival was the sole primary endpoint in the United States for the Phase III EPCORE DLBCL-1 trial...
Proveca seeks re-examination of EMA rejection for pediatric intranasal pain spray KemSu
Denmark-based Cessatech said its commercialization partner Proveca intends to request a re-examination of a negative opinion issued by the European...
Ipsen's Bylvay fails to improve native liver survival in biliary atresia Phase III trial
Ipsen's Phase III BOLD trial of Bylvay (odevixibat) in biliary atresia did not meet its primary endpoint of improving native liver survival versus placebo,...
Infinitopes debuts off-the-shelf esophageal cancer vaccine in clinic
Oxford, England-based Infinitopes has dosed the first patient in a trial testing whether a therapeutic cancer vaccine given before surgery can lower...
J&J's Tecvayli + Talvey combo cuts progression risk 89% in earlier-line relapsed myeloma
Johnson & Johnson (NYSE: JNJ) reported that its combination of two bispecific T-cell engagers reduced the risk of disease progression or death by 89% in...
Synaptiq Therapeutics launches with acquisition of small-molecule rare disease therapy
Synaptiq Therapeutics, an Iceland-based clinical-stage biotechnology company, launched through the acquisition of SYN-001, a small molecule already in...
Transcripta secures USD 24m to advance AI-powered neurological drug platform
Palo Alto, California-based Transcripta Bio, an AI-powered drug discovery company focused on neurological and neuromuscular diseases, has raised USD 24...
Lilly completes retatrutide Phase III package ahead of planned Q1 2027 FDA filing
Eli Lilly and Company (NYSE: LLY) reported positive topline results from two additional Phase III trials of retatrutide, pushing the investigational triple...
FDA begins review of Revolution's RAS(ON) inhibitor for pancreatic cancer
The US Food and Drug Administration has accepted for review Revolution Medicines' New Drug Application for daraxonrasib (RMC-6236), an oral RAS(ON)...
BridgeBio's encaleret advances toward first-ever ADH1 approval with FDA NDA acceptance
BridgeBio Pharma, Inc. (Nasdaq: BBIO) said the US FDA has accepted for filing its New Drug Application for encaleret, an investigational oral calcilytic, in...
N-Zyme Bio secures USD 4.6m Series A to advance pepsin-targeted reflux therapies
Delaware-based N-Zyme Biomedical, a clinical-stage biotechnology company developing pepsin-targeted therapies for reflux disease, has closed a Series A...
The AllSci Brief
Systematic R&D and deal news. Daily.